Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid

Kidney International

Volumn 81, Issue 6, 2012, Pages 559-567

  Jelaković, Bojan ^a   Karanović, Sandra ^a   Vuković Lela, Ivana ^a   Miller, Frederick ^b   Edwards, Karen L ^c   Nikolić, Jovan ^d   Tomić, Karla ^e   Slade, Neda ^f   Brdar, Branko ^f   Turesky, Robert J ^g   Stipancić, Želimir ^h   Dittrich, Damir ^e   Grollman, Arthur P ^b   Dickman, Kathleen G ^b  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b STONY BROOK UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d CLINICAL CENTER OF SERBIA   (Serbia)

^e DR JOSIP BEN EVI GENERAL HOSPITAL   (Croatia)

^f RUDER BO KOVI INSTITUTE   (Croatia)

^g WADSWORTH CENTER   (United States)

^h GENERAL HOSPITAL   (Bosnia and Herzegovina)

Author keywords

Aristolochia; aristolochic acid; DNA adducts; endemic nephropathy; nephrotoxicity; upper urinary tract cancer

Indexed keywords

ARISTOLOCHIC ACID; ARISTOLOLACTAM; PROTEIN P53;

AGED; ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; DISEASE ASSOCIATION; DNA ADDUCT; DNA EXTRACTION; ENVIRONMENTAL EXPOSURE; FEMALE; GENE MUTATION; GENETIC SUSCEPTIBILITY; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN TISSUE; INTERSTITIAL NEPHRITIS; KIDNEY CORTEX; MAJOR CLINICAL STUDY; MALE; MOLECULAR EPIDEMIOLOGY; NEPHROURETERECTOMY; PRIORITY JOURNAL; SEX DIFFERENCE; URINARY TRACT CARCINOMA; UROGENITAL TRACT TUMOR;

EID: 84857765122     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.371     Document Type: Article

References (54)

1. Djukanović L, Radovanović Z. Balkan endemic nephropathy. In: De Broe ME, Porter GA, Bennett WM, Verpooten GA (eds) Clinical Nephrotoxins. 2nd edn, Kluwer: Dordrecht, 2003 pp 588-601.
2. Nikolić J. Epidemic Nephropathy and Upper Urothelial Tumors. Izdavacko Preduzeće Beograd AD: Belgrade, Serbia, 2006.
3. Petronić V. Tumors of the upper urothelium and endemic nephropathy. In: Radovanović Z, Sindić M, Polenaković M, Djukanović L, Petronić V (eds). Endemic Nephropathy. Institute for Textbook Publishing: Belgrade, Serbia, 2000, pp 350-439.
4. Ceović S, Hrabar A, Radonić M. An etiological approach to Balkan endemic nephropathy based on the investigation of two genetically different populations. Nephron 1985; 40: 175-179. (Pubitemid 15064569)
5. Radovanović Z. Epidemiology and aetiology of endemic nephropathy. In: Radovanović Z, Sindić M, Polenaković M, Djukanović L, Petronić V (eds). Endemic Nephropathy. Institute for Textbook Publishing: Belgrade, Serbia, 2000, pp 22-152.
6. Toncheva D, Dimitrov T, Stojanova S. Etiology of Balkan endemic nephropathy: a multifactorial disease? Eur J Epidemiol 1998; 14: 389-394. (Pubitemid 28288463)
7. Bamias G, Boletis J. Balkan nephropathy: evolution of our knowledge. Am J Kidney Dis 2008; 52: 606-616.
8. Voice TC, Long DT, Radovanović Z et al. Critical evaluation of environmental exposure agents suspected in the etiology of Balkan endemic nephropathy. Int J Occup Environ Health 2006; 12: 369-376. (Pubitemid 44877539)
9. Pfohl-Leszkowicz A, Tozlovanu M, Manderville R et al. New molecular and field evidences for the implication of mycotoxins but not aristolochic acid in human nephropathy and urinary tract tumor. Mol Nutr Food Res 2007; 51: 1131-1146. (Pubitemid 47522807)
10. Batuman V. Fifty years of Balkan endemic nephropathy: daunting questions, elusive answers. Kidney Int 2006; 69: 644-646. (Pubitemid 43237631)
11. Ivić M. The problem of etiology of endemic nephropathy. LijecVjes 1969; 91: 1273-1281.
12. Vanherweghem JL, Depierreux M, Tielemans C et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993; 341: 387-391. (Pubitemid 23048140)
13. Nortier JL, Martinez MC, Schmeiser HH et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000; 342: 1686-1692. (Pubitemid 30354515)
14. Cosyns JP, Jadoul M, Squifflet JP et al. Urothelial lesions in Chinese-herb nephropathy. Am J Kidney Dis 1999; 33: 1011-1017. (Pubitemid 29252669)
15. Grollman AP, Shibutani S, Moriya M et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci USA 2007; 104: 12129-12134. (Pubitemid 47185641)
16. Moriya M, Slade N, Brdar B et al. TP53 mutational signature for aristolochic acid: an environmental carcinogen. Int J Cancer 2011; 129: 1532-1536.
17. Olivier M, Eeles R, Hollstein M et al. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002; 19: 607-614. (Pubitemid 34556481)
18. Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int 2008; 74: 158-169. (Pubitemid 351915079)
19. Grollman AP, Scarborough J, Jelaković B. Aristolochic acid nephropathy: an environmental and iatrogenic disease. In: Fishbein J (ed) Advances in Molecular Toxicology. vol. 3 Elsevier: Amsterdam, 2009, pp 211-222.
20. Hranjec T, Kovac A, Kos J et al. Endemic nephropathy: the case for chronic poisoning by Aristolochia. Croat Med J 2005; 46: 116-125. (Pubitemid 40469936)
21. Colin P, Koenig P, Ouzzane A et al. Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int 2009; 104: 1436-1440.
22. Cosyns JP, Jadoul M, Squifflet JP et al. Chinese herbs nephropathy: a clue to Balkan endemic nephropathy? Kidney Int 1994; 45: 1680-1688. (Pubitemid 24207504)
23. World Health Organization, International Agency for Research on Cancer, some traditional herbal medicines, some mycotoxins, naphthalene and styrene: Aristolochia species and aristolochic acids. IARC Monogr Eval Carcinog Risks Hum 2002; 82: 69-128.
24. National Toxicology Program. Aristolochic acids. Rep Carcinog 2011; 12: 45-49.
25. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295-300.
26. Jarabek AM, Pottenger LH, Andrews LS et al. Creating context for the use of DNA adduct data in cancer risk assessment: I. Data organization. Crit Rev Toxicol 2009; 39: 659-678.
27. Swenberg JA, Fryar-Tita E, Jeong YC et al. Biomarkers in toxicology and risk assessment: informing critical dose-response relationships. Chem Res Toxicol 2008; 21: 253-265. (Pubitemid 351219722)
28. Martincić M. Toxische einwirkungen der Aristolochia clematitis auf die Niere des Pferdes. Veterinarski Archiv 1958; 27: 51-59.
29. Cukuranović R, Jovanović I, Miljković S et al. Hemodialysis treatment in patients with Balkan endemic nephropathy: an epidemiological study. Ren Fail 2007; 29: 805-810. (Pubitemid 350125661)
30. Belicza M, Demirović A, Tomić K et al. Comparison of occurrence of upper urinary tract carcinomas in the region with endemic villages and non-endemic nephropathy region in Croatia. Coll Antropol 2008; 32: 1203-1207.
31. Krogh P. Mycotoxin porcine nephropathy: a possible model for Balkan endemic nephropathy. In: Puchlev A (ed). Endemic Nephropathy. Bulgarian Academy of Science: Sofia, Bulgaria, 1974, pp 266-270.
32. Radić B, Fuchs R, Peraica M et al. Ochratoxin A in human sera in the area with endemic nephropathy in Croatia. Toxicol Lett 1997; 91: 105-109. (Pubitemid 27214561)
33. Clark HA, Snedeker SM. Ochratoxin A: its cancer risk and potential for exposure. J Toxicol Environ Health B Crit Rev 2006; 9: 265-296.
34. Godin M, Fillastre JP, Simon P et al. Is ochratoxin A nephrotoxic in human beings? Adv Nephrol Necker Hosp 1997; 26: 181-206.
35. Fink-Gremmels J. Ochratoxin A in food: recent developments and significance. Food Addit Contam 2005; 22(Suppl 1): 1-5.
36. Cavin C, Delatour T, Marin-Kuan M et al. Ochratoxin A-mediated DNA and protein damage: roles of nitrosative and oxidative stresses. Toxicol Sci 2009; 110: 84-94.
37. Palma N, Cinelli S, Sapora O et al. Ochratoxin A-induced mutagenesis in mammalian cells is consistent with the production of oxidative stress. Chem Res Toxicol 2007; 20: 1031-1037. (Pubitemid 47204816)
38. Mantle PG, Faucet-Marquis V, Manderville RA et al. Structures of covalent adducts between DNA and ochratoxin A: a new factor in debate about genotoxicity and human risk assessment. Chem Res Toxicol 2010; 23: 89-98.
39. Delatour T, Mally A, Richoz J et al. Absence of 20-deoxyguanosine-carbon 8-bound ochratoxin A adduct in rat kidney DNA monitored by isotope dilution LC-MS/MS. Mol Nutr Food Res 2008; 52: 472-482.
40. Peluso M, Castegnaro M, Malaveille C et al. 32P-postlabelling analysis of DNA adducted with urinary mutagens from smokers of black tobacco. Carcinogenesis 1990; 11: 1307-1311. (Pubitemid 20245702)
41. Cosyns JP. Aristolochic acid and 'Chinese herbs nephropathy': a review of the evidence to date. Drug Saf 2003; 26: 33-48.
42. Chen HY, Ma BY, Grant A et al. Time to abandon the term "Chinese herbs nephropathy". Kidney Int 2001; 60: 2039-2040. (Pubitemid 33000015)
43. Shibutani S, Dong H, Suzuki N et al. Selective toxicity of aristolochic acids I and II. Drug Metab Dispos 2007; 35: 1217-1222. (Pubitemid 46956445)
44. Shibutani S, Bonala RR, Rosenquist T et al. Detoxification of aristolochic acid I by O-demethylation: less nephrotoxicity and genotoxicity of aristolochic acid Ia in rodents. Int J Cancer 2010; 127: 1021-1027.
45. Rosenquist TA, Einolf HJ, Dickman KG et al. Cytochrome P450 1A2 detoxicates aristolochic acid in the mouse. Drug Metab Dispos 2010; 38: 761-768.
46. Kabanda A, Jadoul M, Lauwerys R et al. Low molecular weight proteinuria in Chinese herbs nephropathy. Kidney Int 1995; 48: 1571-1576.
47. Poirier MC, Santella RM, Weston A. Carcinogen macromolecular adducts and their measurement. Carcinogenesis 2000; 21: 353-359. (Pubitemid 30137920)
48. Dickman KG, Sweet DH, Bonala R et al. Physiological and molecular characterization of aristolochic acid transport by the kidney. J Pharmacol Exp Ther 2011; 338: 588-597.
49. Hu SL, Zhang HQ, Chan K et al. Studies on the toxicity of Aristolochia manshuriensis (Guanmuton). Toxicology 2004; 198: 195-201. (Pubitemid 38609028)
50. Hsieh SC, Lin IH, Tseng WL et al. Prescription profile of potentially aristolochic acid containing Chinese herbal products: an analysis of national health insurance data in Taiwan between 1997 and 2003. Chin Med 2008; 3: 13.
51. Lai MN, Wang SM, Chen PC et al. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst 2010; 102: 179-186.
52. Levey AS, Coresh J, Greene T et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254. (Pubitemid 46768608)
53. Levey AS, Eckardt KU, Tsukamoto Y et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089-2100. (Pubitemid 41623371)
54. Dong H, Suzuki N, Torres MC et al. Quantitative determination of aristolochic acid-derived DNA adducts in rats using 32P-postlabeling/ polyacrylamide gel electrophoresis analysis. Drug Metab Dispos 2006; 34: 1122-1127.